Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery
- PMID: 25344308
- DOI: 10.1245/s10434-014-4195-3
Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery
Abstract
Background: Some esophageal cancer patients may have residual nodal metastases following pathologic complete response (pCR) of the primary tumor after neoadjuvant chemoradiotherapy (CRT). This study examines the prognosis according to lymph node metastases in pathologic T0 patients who received neoadjuvant CRT followed by surgery for esophageal squamous cell carcinoma (SCC).
Methods: Prospectively-collected data from patients who underwent protocol-based esophageal resection and reconstruction after neoadjuvant CRT for esophageal SCC from 2000 to 2010 at the Asan Medical Center, Seoul, Korea, were retrospectively studied. Overall survival (OS), recurrence-free survival (RFS), and risk factors for ypT0N1 were analyzed and compared with ypT0N0.
Results: A total of 211 patients underwent prospective, protocol-based esophageal resection and reconstruction after neoadjuvant CRT for esophageal SCC. Of these, 123 patients had a pCR of the primary tumor and were enrolled in this study. Lymph node status was ypT0N0 in 103 patients and ypT0N1 in 20 patients. The two groups did not show significant differences in sex, initial clinical stage, tumor location, and histologic grade. Recurrence occurred in 13 patients (12.6 %) with ypT0N0 and six patients (30.0 %) with ypT0N1, respectively (p = 0.083). Five-year OS and RFS of ypT0N1 were 42.8 ± 13.9 and 41.7 ± 12.8 %, respectively. Survival was compared between the two groups using a log-rank test, and there were no significant differences for OS or RFS.
Conclusions: Residual lymph node metastases did not significantly influence prognosis in pathologic T0 patients who received neoadjuvant CRT followed by surgery for esophageal SCC.
Similar articles
-
The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.J Surg Oncol. 2015 Nov;112(6):597-602. doi: 10.1002/jso.24050. Epub 2015 Sep 23. J Surg Oncol. 2015. PMID: 26394724
-
Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.Dis Esophagus. 2005;18(6):388-97. doi: 10.1111/j.1442-2050.2005.00521.x. Dis Esophagus. 2005. PMID: 16336610
-
The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.Ann Surg Oncol. 2014 Sep;21(9):2845-9. doi: 10.1245/s10434-014-3688-4. Epub 2014 Apr 14. Ann Surg Oncol. 2014. PMID: 24728820
-
Frequency and distribution pattern of lymph node metastasis after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.J Cancer Res Clin Oncol. 2024 Oct 24;150(10):476. doi: 10.1007/s00432-024-05967-0. J Cancer Res Clin Oncol. 2024. PMID: 39448397 Free PMC article. Review.
-
[Management of esophageal squamous cell carcinoma and adenocarcinoma: surgical, endoscopic, and radiotherapeutic options].Med Clin (Barc). 2012 Dec 1;139(13):588-92. doi: 10.1016/j.medcli.2012.05.024. Epub 2012 Jul 28. Med Clin (Barc). 2012. PMID: 22841469 Review. Spanish. No abstract available.
Cited by
-
Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma.BMC Cancer. 2025 Jan 10;25(1):61. doi: 10.1186/s12885-025-13465-w. BMC Cancer. 2025. PMID: 39794758 Free PMC article.
-
ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up?J Thorac Dis. 2018 May;10(5):2771-2778. doi: 10.21037/jtd.2018.04.136. J Thorac Dis. 2018. PMID: 29997939 Free PMC article.
-
Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.Cancer Control. 2024 Jan-Dec;31:10732748241284905. doi: 10.1177/10732748241284905. Cancer Control. 2024. PMID: 39259832 Free PMC article.
-
Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma.Cancer Med. 2025 Feb;14(4):e70676. doi: 10.1002/cam4.70676. Cancer Med. 2025. PMID: 39945301 Free PMC article.
-
Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysis.Medicine (Baltimore). 2017 Jun;96(26):e7342. doi: 10.1097/MD.0000000000007342. Medicine (Baltimore). 2017. PMID: 28658150 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials